A safety and bioequivalence study of doxorubicin hydrochloride liposome injection (TLC177) in patients with advanced ovarian carcinoma

Trial Profile

A safety and bioequivalence study of doxorubicin hydrochloride liposome injection (TLC177) in patients with advanced ovarian carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 19 May 2017 According to a Taiwan Liposome Company media release, based on the data from this study, the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for TLC177 (liposomal doxorubicin) in the treatment of breast cancer and ovarian cancer.
    • 06 Oct 2016 New trial record
    • 02 Sep 2016 Preliminary results published in a Taiwan Liposome Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top